

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



深圳市海王英特龍生物技術股份有限公司

**SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED\***

*(a joint stock limited company incorporated in the People's Republic of China)*

**(Stock Code: 8329)**

## **INSIDE INFORMATION ANNOUNCEMENT PROFIT WARNING**

This announcement is made by Shenzhen Neptunus Interlong Bio-technique Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the Shareholders and potential investors that, based on the assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 (the “**2026 Interim Period**”) and other information currently available, the Group is expected to record a net profit attributable to the owners of the Company of approximately RMB7 million for the 2026 Interim Period, as compared to a net profit attributable to the owners of the Company of approximately RMB19.07 million for the six months ended 30 June 2025. The primary reason for the aforesaid decrease in net profit attributable to the owners of the Company is that, affected by market conditions and policies, the Group’s revenue decreased by approximately 12%, which is mainly attributable to the revenue reduction from the segment of manufacturing and selling of medicines and medical devices.

As the Group is still in the process of finalising its results for the 2026 Interim Period, shareholders and potential investors are advised to refer to the details in the results announcement of the Group for the 2026 Interim Period which is expected to be published on 25 August 2026.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Shenzhen Neptunus Interlong Bio-technique Company Limited\***  
**Zhang Feng**  
*Chairman*

Shenzhen, the PRC, 12 August 2026

*As at the date of this announcement, the executive Directors are Mr. Zhang Feng, Mr. Huang Jian Bo and Mr. Zhang Xiao Guang; the non-executive Directors are Mr. Zhang Yi Fei, Mr. Jin Rui and Mr. Zhang Xiao Peng; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Ms Zhu Jia Min.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at [www.hkexnews.hk](http://www.hkexnews.hk) for at least 7 days from its date of publication and on the Company’s website at [www.interlong.com](http://www.interlong.com).*

\* For identification purpose only